Breast cancer statistics, 2019
暂无分享,去创建一个
Ahmedin Jemal | A. Jemal | R. Siegel | L. Newman | K. Miller | Jiemin Ma | C. DeSantis | Ann Goding Sauer | M. Gaudet | Mia M Gaudet | Lisa A Newman | Jiemin Ma | Rebecca L Siegel | Kimberly D Miller | Carol E DeSantis | Ann Goding Sauer | K. D. Miller
[1] L. Newman,et al. Health Disparities and Triple-Negative Breast Cancer in African American Women: A Review , 2017, JAMA surgery.
[2] Rebecca L. Siegel Mph,et al. Cancer statistics, 2018 , 2018 .
[3] C. Parise,et al. Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California. , 2014, Cancer epidemiology.
[4] B. Sommers,et al. Changes in Mortality After Massachusetts Health Care Reform , 2014, Annals of Internal Medicine.
[5] Eric J Feuer,et al. The decrease in breast-cancer incidence in 2003 in the United States. , 2007, The New England journal of medicine.
[6] Sung-Bae Kim,et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy , 2017, The New England journal of medicine.
[7] Ruth Etzioni,et al. Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States , 2017, Cancer Epidemiology, Biomarkers & Prevention.
[8] Eric P. Winer,et al. Breast Cancer Treatment: A Review , 2019, JAMA.
[9] Peter W. Laird,et al. Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas , 2017, JAMA oncology.
[10] Ahmedin Jemal,et al. Cancer treatment and survivorship statistics, 2019 , 2019, CA: a cancer journal for clinicians.
[11] K. McGuire,et al. Are Mastectomies on the Rise? A 13-Year Trend Analysis of the Selection of Mastectomy Versus Breast Conservation Therapy in 5865 Patients , 2009, Annals of Surgical Oncology.
[12] S. Ingles,et al. Reproductive history, breast‐feeding and risk of triple negative breast cancer: The Breast Cancer Etiology in Minorities (BEM) study , 2018, International journal of cancer.
[13] A. Jemal,et al. Cancer treatment and survivorship statistics, 2016 , 2016, CA: a cancer journal for clinicians.
[14] J. Gentleman,et al. Update on mammography trends , 2011, Cancer.
[15] O. Olopade,et al. A perfect storm: How tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change , 2015, CA: a cancer journal for clinicians.
[16] M. Hurlbert,et al. Black:white disparities in breast cancer mortality in the 50 largest cities in the United States, 2005-2014. , 2016, Cancer epidemiology.
[17] A. Jemal,et al. Breast cancer subtypes among Eastern‐African–born black women and other black women in the United States , 2019, Cancer.
[18] D. Silverman,et al. Cancer incidence and mortality trends among whites in the United States, 1947-84. , 1987, Journal of the National Cancer Institute.
[19] P. Cordeiro,et al. Bilateral Mastectomy versus Breast-Conserving Surgery for Early-Stage Breast Cancer: The Role of Breast Reconstruction , 2015, Plastic and reconstructive surgery.
[20] Abigail Silva,et al. Racial/Ethnic Disparities in Time to a Breast Cancer Diagnosis: The Mediating Effects of Health Care Facility Factors , 2015, Medical care.
[21] R. Barrett,et al. Multilevel Examination of Health Disparity: The Role of Policy Implementation in Neighborhood Context, in Patient Resources, and in Healthcare Facilities on Later Stage of Breast Cancer Diagnosis , 2018, Cancer Epidemiology, Biomarkers & Prevention.
[22] E. Winer,et al. Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Gretchen L. Gierach,et al. Pooled Analysis of Nine Cohorts Reveals Breast Cancer Risk Factors by Tumor Molecular Subtype. , 2018, Cancer research.
[24] Charles Kooperberg,et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.
[25] P. Fasching,et al. Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer , 2019, The New England journal of medicine.
[26] A. Jemal,et al. Trends in stage at diagnosis for young breast cancer patients in the United States , 2018, Breast Cancer Research and Treatment.
[27] Philip S Rosenberg,et al. Incidence of breast cancer in the United States: current and future trends. , 2011, Journal of the National Cancer Institute.
[28] R. Wolff,et al. The Interaction between Genetic Ancestry and Breast Cancer Risk Factors among Hispanic Women: The Breast Cancer Health Disparities Study , 2016, Cancer Epidemiology, Biomarkers & Prevention.
[29] J. Lortet-Tieulent,et al. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. , 2015, JAMA.
[30] R. Hiatt,et al. Trends and disparities in socioeconomic and behavioural characteristics, life expectancy, and cause-specific mortality of native-born and foreign-born populations in the United States, 1979-2003. , 2006, International journal of epidemiology.
[31] Kevin A. Henry,et al. Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State , 2015, Journal of the National Cancer Institute.
[32] J. Boughey,et al. Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes , 2018, Annals of surgical oncology.
[33] Timothy J Wilt,et al. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. , 2009, Annals of internal medicine.
[34] A. Jemal,et al. Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.
[35] Yu Shyr,et al. Nationwide trends in mastectomy for early-stage breast cancer. , 2015, JAMA surgery.
[36] Oguzhan Alagoz,et al. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. , 2014, Journal of the National Cancer Institute.
[37] Virginia G Kaklamani,et al. Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer , 2018, The New England journal of medicine.
[38] Richard J. K. Taylor,et al. The impact of changes in hormone therapy on breast cancer incidence in the US population , 2009, Cancer Causes & Control.
[39] N. Keating,et al. Receipt of locoregional therapy among young women with breast cancer , 2012, Breast Cancer Research and Treatment.
[40] A. Jemal,et al. State Variation in the Receipt of a Contralateral Prophylactic Mastectomy Among Women Who Received a Diagnosis of Invasive Unilateral Early-Stage Breast Cancer in the United States, 2004-2012 , 2017, JAMA surgery.
[41] L. Newman. Parsing the Etiology of Breast Cancer Disparities. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] J. Martin,et al. Births: Final Data for 2017. , 2018, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[43] W. Satariano,et al. Cancer Research in Asian American, Native Hawaiian, and Pacific Islander Populations: Accelerating Cancer Knowledge by Acknowledging and Leveraging Heterogeneity , 2014, Cancer Epidemiology, Biomarkers & Prevention.
[44] T. Wilt,et al. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. , 2009, Annals of internal medicine.
[45] E. Winer,et al. Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.
[46] Ping Sun,et al. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. , 2015, JAMA.
[47] H. Nelson,et al. Incident Cases Captured in the National Cancer Database Compared with Those in U.S. Population Based Central Cancer Registries in 2012–2014 , 2019, Annals of Surgical Oncology.
[48] S. Gomez,et al. Breast Cancer Mortality in African-American and Non-Hispanic White Women by Molecular Subtype and Stage at Diagnosis: A Population-Based Study , 2015, Cancer Epidemiology, Biomarkers & Prevention.
[49] Oguzhan Alagoz,et al. Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012 , 2018, JAMA.
[50] A. Jemal,et al. Breast Cancer Incidence Rates in U.S. Women Are No Longer Declining , 2011, Cancer Epidemiology, Biomarkers & Prevention.
[51] L. Mobley,et al. Update on triple‐negative breast cancer disparities for the United States: A population‐based study from the United States Cancer Statistics database, 2010 through 2014 , 2019, Cancer.
[52] S. Altekruse,et al. The impact of follow-up type and missed deaths on population-based cancer survival studies for Hispanics and Asians. , 2014, Journal of the National Cancer Institute. Monographs.
[53] Jennifer L. Caswell-Jin,et al. Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review , 2018, JNCI cancer spectrum.
[54] D. Berry,et al. Effect of screening and adjuvant therapy on mortality from breast cancer , 2005 .
[55] W. Gradishar,et al. Triple-Negative Breast Cancer: Current Practice and Future Directions. , 2017, Journal of oncology practice.
[56] N. Howlader,et al. Differences in Breast Cancer Survival by Molecular Subtypes in the United States , 2018, Cancer Epidemiology, Biomarkers & Prevention.
[57] Vanessa M. Hubbard-Lucey,et al. Immunotherapy and targeted therapy combinations in metastatic breast cancer. , 2019, The Lancet. Oncology.
[58] M. Gail,et al. Proportion of U.S. Trends in Breast Cancer Incidence Attributable to Long-term Changes in Risk Factor Distributions , 2018, Cancer Epidemiology, Biomarkers & Prevention.